Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe 07:32:13 2024-04-29 am EDT 5-day change 1st Jan Change
368.5 SEK -1.21% Intraday chart for Xvivo Perfusion AB +17.52% +11.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague CI
Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 16-MAR-2024. CI
Nordic Shares Moved Upward Thursday; Nokia Topped Leaders DJ
Transcript : Xvivo Perfusion AB, 2023 Earnings Call, Jan 25, 2024
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss DJ
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published CI
Transcript : Xvivo Perfusion AB, Q3 2023 Earnings Call, Oct 24, 2023
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial CI
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee CI
Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue MT
Xvivo Perfusion Gets USFDA Nod on Using Donated Hearts in Heart Preservation Clinical Trial MT
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial CI
Transcript : Xvivo Perfusion AB, Q2 2023 Earnings Call, Jul 13, 2023
Xvivo Perfusion Closes PrimECC Trial Amid Patient Recruitment Challenges MT
Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Xvivo Perfusion AB Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated CI
XVIVO Perfusion AB Enters into A Strategic Collaboration with MTJ Aviation to Strengthen Organ Procurement Services in the US CI
Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology CI
Patient Inclusion Completed in European Clinical Trial with XVIVO's Heart Preservation Technology CI
Chart Xvivo Perfusion AB
More charts
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
373 SEK
Average target price
408 SEK
Spread / Average Target
+9.38%
Consensus
  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. News Xvivo Perfusion AB
  5. Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue